Assembly Biosciences (NASDAQ:ASMB) Trading Up 8.2% on Strong Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB)’s share price rose 8.2% during mid-day trading on Friday following a better than expected earnings announcement. The company traded as high as $32.26 and last traded at $32.4140. Approximately 219,868 shares traded hands during mid-day trading, an increase of 47% from the average daily volume of 149,415 shares. The stock had previously closed at $29.95.

The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 8.98% and a negative return on equity of 4.21%. The firm had revenue of $13.37 million during the quarter, compared to the consensus estimate of $8.60 million.

Wall Street Analyst Weigh In

ASMB has been the topic of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a research note on Monday, May 4th. Wall Street Zen cut shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. Mizuho set a $45.00 price target on Assembly Biosciences and gave the company an “outperform” rating in a report on Monday, June 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Finally, Guggenheim reissued a “buy” rating and issued a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Institutional Trading of Assembly Biosciences

Several large investors have recently bought and sold shares of ASMB. Stempoint Capital LP increased its stake in Assembly Biosciences by 18.3% during the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock worth $5,146,000 after buying an additional 28,707 shares during the period. Eversept Partners LP acquired a new position in Assembly Biosciences in the 4th quarter worth $5,431,000. 683 Capital Management LLC purchased a new position in Assembly Biosciences in the 4th quarter valued at about $948,000. Bank of America Corp DE boosted its position in Assembly Biosciences by 113.3% in the 1st quarter. Bank of America Corp DE now owns 10,902 shares of the biopharmaceutical company’s stock valued at $303,000 after buying an additional 5,792 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Assembly Biosciences by 69.4% during the first quarter. Renaissance Technologies LLC now owns 15,651 shares of the biopharmaceutical company’s stock valued at $434,000 after acquiring an additional 6,411 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

Assembly Biosciences Stock Up 8.2%

The company has a market capitalization of $515.07 million, a price-to-earnings ratio of -293.55 and a beta of 1.10. The firm has a 50 day moving average price of $25.89 and a two-hundred day moving average price of $27.34.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.